Important note

This AI stock analysis for Iovance Biotherapeutics is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Iovance Biotherapeutics - AI Stock Analysis

Analysis generated June 3, 2025

Iovance Biotherapeutics is a biotech company specializing in the development and commercialization of innovative cancer immunotherapies. The company focuses on leveraging the power of tumor-infiltrating lymphocytes (TILs) to treat cancer, providing a novel approach in the oncology therapeutic landscape.

Fundamental Analysis

The company's revenue for the last quarter was $49 million. This represents a decrease of 33.07% compared to the previous quarter, a troubling sign for potential short-term investors. However, compared to the same quarter last year, the revenue has surged by an astonishing 6798.46%, indicating remarkable year-over-year growth.

The net income for the last quarter was -$116 million. This represents a decrease of 47.87% compared to the previous quarter, suggesting a significant decrease in profitability. Compared to the same quarter last year, the decrease is marginal at 2.82%, signaling a persistent challenge in maintaining profitability.

The EBITDA for the last quarter was $0, showcasing an increase of 100.00% compared to the previous quarter and representing positive year-over-year growth. This signifies an operational improvement as the company may have streamlined its operations to minimize operational losses.

Technical Analysis

Today's stock price is $1.76, representing a sharp decline of 49.71% compared to a month ago. This is concerning for short-term investors. Over the past year, the stock has plummeted by 78.27%, raising concerns about the company's long-term stability. The general trend is bearish.

The current Simple Moving Average (SMA10) is $1.76, which is slightly lower than the previous SMA10 of $1.77, suggesting a potential sustained downward trend in future price movements. The Relative Strength Index (RSI) stands at 47.7, signifying a neutral condition.

Alternative Data Analysis

Regarding job postings and employee sentiment, Iovance Biotherapeutics has 39 open positions. This number is down by 70% in the last couple of months, indicating attempts to improve margins or cut costs. This is not an ideal scenario for a growth-oriented company.

The business outlook among employees is neutral. The number of visitors to their webpage is estimated to be 24,000, which is down by 8% in the last couple of months. This decreasing trend is worrisome as it may indicate customer loss. However, their Twitter page has seen an increase of 5% in followers, bringing the total to 1,700. This shows a slight increase in public interest in the company.

The AltIndex AI score for Iovance Biotherapeutics is 54, which signals a hold. This score integrates fundamental, technical, and alternative data to provide a comprehensive view of the company's future prospects.

Conclusion and Recommendation

Iovance Biotherapeutics presents a mixed bag for potential investors. On the one hand, the company has shown significant year-over-year revenue growth and operational improvements marked by a positive EBITDA shift. However, the company is facing challenges with decreased revenue and net income quarter-over-quarter, substantial stock price declines, and bearish technical indicators. Alternative data provides further caution with reduced job postings and website visitors, though there is a slight uptick in social media engagement.

Given these factors, a cautious stance is recommended. The hold signal from the AltIndex AI score aligns well with the mixed signals from the fundamental, technical, and alternative data analyses. Therefore, it may be prudent for investors to maintain a hold position, closely monitoring future data points for more definitive trends before making further investment decisions.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.